Revolution in the operation: New scanner drastically reduces breast cancer surgery!

Revolution in the operation: New scanner drastically reduces breast cancer surgery!

The St. Vincenz clinics in Paderborn have developed a new high-tech scanner that revolutionizes the analysis of tissue samples during breast cancer surgery. This scanner, a confocal laser microscope, was successfully tested in a study, the results of which were presented in the USA in the USA in the United States. According to the results of this study, the risk of follow -up operations could be significantly reduced, which represents a remarkable medical development.

Prof. Dr. Michael Patrick Lux, chief physician and head of the study, emphasizes the advantages of the scanner: "The technology enables more precise analyzes that take place directly at the operating table. Within just a minute, the scanner can generate pathological images of the wound edges." The aim of the operation is to completely remove the affected tissue while intact tissue shares are preserved. This contributes to medical security and reduces cosmetic impairments for patients.

results of the study

The study carried out reduced the number of follow -up operations by impressive two thirds. In the prospective Shield study, which took place at the St. Vincenz Hospital, the reoperation rates were reduced from 30% to 10% after breast-conserving operations. These results were compared with historical data from the Polarhis study, which used standardized techniques for intraoperative marginal evaluation.

The histologous scanner had a sensitivity of 80.9% and a specificity of 99.5% in identification of positive wound edges. In contrast, traditional evaluation methods only had a combined sensitivity of 17.4% and a specificity of 97.3%. These significant differences show the potential of the new device in clinical practice.

future application and meaning

The innovative device was developed by Saman Tree Medical in Switzerland. The company plans to speed up the market in the USA after it received the 510 (K) approval from the US Food and Drug Administration (FDA) in September. The St. Vincenz Hospital is expected to remain the only study center worldwide. The positive results of the scanner could be used worldwide, provided that the financing of the high-tech devices is clarified.

The importance of this development is underlined by the fact that breast cancer is the most common cancer in women, and men are also affected in 0.5–1% of cases. Timely detection and precise treatment options are crucial for the success of the treatment.